1
584 Journal of Natural Products, 2008, Vol. 71, No. 9
Pontius et al.
drug dilutions in microtiter plates for 48 h at 37 °C in a gas mixture
with reduced O and elevated CO . [ H]Hypoxanthine was added to
2 2
(2) Molinar-Toribio, E.; Gonz a´ lez, J.; Ortega-Barr ´ı a, E.; Capson, T. L.;
Coley, P. D.; Kursar, T. A.; McPhail, K.; Cubilla-Rios, L. Pharm.
Biol. 2006, 44, 550–553.
3
each well, and after further incubation for 24 h the wells were harvested
on glass fiber filters and counted in a liquid scintillation counter. From
the sigmoidal inhibition curve the IC50 value was calculated. Chloro-
quine was used as positive control in each test series. Activity against
Trypanosoma brucei rhodesiense (strain STIB 900), the causative agent
(
3) Dua, V. K.; Ojha, V. P.; Roy, R.; Joshi, B. C.; Valecha, N.; Usha
Devi, C.; Bhatnagar, M. C.; Sharma, V. P.; Subbarao, S. K. J.
Ethnopharmacol. 2004, 95, 247–251.
(
(
4) Ignatushchenko, M. V.; Winter, R. W.; Riscoe, M. Am. J. Med. Hyg.
2
000, 62, 77–81.
2
9
of African sleeping sickness, was evaluated according to R a¨ z et al.
5) Ridley, R. G. Nature 2002, 415, 686–693.
Parasites were grown axenically in culture medium supplemented with
horse serum. Following a 3-day exposure to compounds 1, 2, and 3,
the viability of tryptomastigote parasites was quantified using the dye
Almar Blue by monitoring the reductive environment of living cells.
Fluorescence development was expressed as percentage of the control,
and IC50 values were calculated. Melarsoprol was included as positive
control. Activity against Trypanosoma cruzi, the causative agent of
Chagas’ disease, was determined according to Buckner et al. Briefly,
the strain Tulahuen C4 of T. cruzi, which had been transfected with
the galactosidase lac-Z gene, was cultivated for 4 days on rat skeletal
(6) Gelb, M. H.; Hol, W. G. J. Science 2002, 297, 343–344.
(7) Egan, T. J.; Kaschula, C. H. Curr. Opin. Infect. Dis. 2007, 20, 598–
604.
(8) Wu, C.-P.; van Schalkwyk, D. A.; Taylor, D.; Smith, P. J.; Chibale,
K. Int. J. Antimicrob. Agents 2005, 26, 170–175.
(
9) Isaka, M.; Jaturapat, A.; Rukseree, K.; Danwisetkanjana, K.; Tanti-
charoen, M.; Thebtaranonth, Y. J. Nat. Prod. 2001, 64, 1015–1018.
30
(10) Portela, C.; Afonso, C. M. M.; Pinto, M. M. M.; Lopes, D.; Nogueira,
F.; do Ros a´ rio, V. Chem. BiodiVersity 2007, 4, 1508–1519.
11) Mahabusarakam, W.; Kuaha, K.; Wilairat, P.; Taylor, W. C. Planta
Med. 2006, 72, 912–916.
(
(
2
myoblasts (5% CO , 37 °C) in the presence of drug. For measurement
12) Hay, A.-E.; H e´ lesbeux, J.-J.; Duval, O.; Laba ¨ı ed, M.; Grellier, P.;
of the IC50 the substrate chlorophenol red-ꢀ-D-galactopyranoside was
added. The enzyme catalyzed the hydrolysis to the red-colored product
that was quantified during the following 2-4 h photometrically
employing an ELISA reader. As a positive control, benznidazole was
included in each test series. Evaluation of antileishmanial activity was
carried out in mouse peritoneal macrophages. The ratio of infection
with Leishmania donoVani (strain MHOM-ET-67/L82), the causative
agent of Kala-Azar disease, was determined microscopically after
exposure to test compounds, incubation, and staining with Giemsa. IC50
values were calculated by linear regression. Miltefosine was used as
positive control. An additional reference cytotoxicity assay was
evaluated in rat skeletal myoblasts (L6-cells), using podophyllotoxin
as positive control.
Richomme, P. Life Sci. 2004, 75, 3077–3085.
(13) Portela, C.; Afonso, C. M. M.; Pinto, M. M. M.; Ramos, M. J. Bioorg.
Med. Chem. 2004, 12, 3313–3321.
(14) Ignatushchenko, M. V.; Winter, R. W.; B a¨ chinger, H. P.; Hinrichs,
D. J.; Riscoe, M. K. FEBS Lett. 1997, 409, 67–73.
(
(
(
15) Altona, C. Encyclopedia Magn. Reson. 1996, 8, 4909–4923.
16) Seco, J. M.; Qui n˜ o a´ , E.; Riguera, R. Chem. ReV. 2004, 104, 17–117.
17) Maskey, R. P.; Gr u¨ n-Wollny, I.; Laatsch, H. J. Antibiot. 2003, 56,
4
59–463.
18) Townsend, C. A.; Isomura, Y.; Davis, S. G.; Hodge, J. A. Tetrahedron
989, 45, 2263–2276.
(
1
(19) O’Malley, G. J.; Murphy, R. A.; Cava, M. P. J. Org. Chem. 1985, 50,
5533–5537.
(20) Yu, J.; Bhatnagar, D.; Cleveland, T. E. FEBS Lett. 2004, 564, 126–
1
30.
Acknowledgment. We thank M. Engeser and C. Sondag, University
of Bonn, Germany, for recording EIMS spectra, C. Siering, Institute
for Organic Chemistry, University of Bonn, Germany, for the CD
analyses, and A. Maier as well as H.-H. Fiebig for cytotoxicity assays.
For financial support we thank the Bundesministerium f u¨ r Bildung and
Forschung (BMBF), research program 03F0415A.
(
21) Bringmann, G.; Noll, T. F.; Gulder, T. A. M.; Gr u¨ ne, M.; Dreyer,
M.; Wilde, C.; Pankewitz, F.; Hilker, M.; Payne, G. D.; Jones, A. L.;
Goodfellow, M.; Fiedler, H.-P. Nat. Chem. Biol. 2006, 2, 429–433.
22) Gales, L; Damas, A. M. Curr. Med. Chem. 2005, 12, 2499–2515.
23) Shimada, A.; Takahashi, I.; Kawano, T.; Kimura, Y. Z. Naturforsch.
B 2001, 56, 797–803.
(
(
(24) Kachi, H.; Hattori, H.; Sassa, T. J. Antibiot. 1986, 39, 164–166.
(25) Ward, D. E.; Rhee, C. K. Tetrahedron Lett. 1991, 32, 7165–7166.
(26) Schulz, B.; Sucker, J.; Aust, H.-J.; Krohn, K.; Ludewig, K.; Jones,
P. G.; D o¨ ring, D. Mycol. Res. 1995, 99, 1007–1015.
Supporting Information Available: Key COSY and HMBC
1
13
correlations, H and C NMR spectra, as well as the proposed
biogenesis of compounds 1-3 additional to a figure with related fungal
metabolites. Figures with calculated torsion angles, results of modified
Mosher’s method, and calculated models of 1. Figures with calculated
models of 3. This material is available free of charge via the Internet
at http://pubs.acs.org.
(27) Dengler, W. A.; Schulte, J.; Berger, D. P.; Mertelsmann, R.; Fiebig,
H.-H. Anticancer Drugs 1995, 6, 522–532.
(
28) Fiebig, H.-H.; Maier, A.; Burger, A. M. Eur. J. Cancer 2004, 40,
8
02–820.
(
29) R a¨ z, B.; Iten, M.; Grether-B u¨ hler, R.; Kaminsky, R.; Brun, R. Acta
Trop. 1997, 68, 139–147.
References and Notes
(30) Bruckner, F. S.; Verlinde, C. L. M. J.; La Flamme, A. C.; van Voorhis,
W. C. Antimicrob. Agents Chemother. 1996, 40, 2592–2597.
(1) Pinto, M. M. M.; Sousa, M. E.; Nascimento, M. S. J. Curr. Med. Chem.
2
005, 12, 2517–2538.
NP800294Q